Urine test may identify human papillomavirus accurately
the ONA take:
According to a new study published in The BMJ, researchers say a urine screening may be accurate at identifying human papillomavirus (HPV). In the study, researchers analyzed 14 studies that tested both the Papanicolaou (Pap) smear test and a urine test to test for HPV in nearly 1,500 sexually active women.
The researchers found that the sensitivity of urine HPV screening was 87% on average and specificity was 94% versus a Pap smear. When researchers only looked at identifying HPV types 16 and 18, the strains that cause cervical cancer and which Gardasil protects against, sensitivity was 73% while specificity was 98%. Researchers note that urine HPV testing accuracy improved when a patient's first-void, first urine sample of the day, was used.
The researchers suggest that urine testing for HPV may be an acceptable alternative to a Pap smear, especially for those who require increased coverage for subgroups that are difficult to reach; however, they also note that there was variation between individual studies, and therefore, the results should be interpreted with caution. Further studies are warranted before urine testing for HPV should be recommended in the clinical setting.
Researchers say a urine screening may be accurate at identifying HPV.
The most common screening method for human papillomavirus (HPV) is a Papanicolaou (Pap) test, also known as a smear test. This involves a doctor or nurse scraping cells from the opening of a woman's cervix, before sending them to a laboratory to be analyzed for abnormalities.
The American Cancer Society claim that between 1955 and 1992, death rates from cervical cancer fell by almost 70% due to increased Pap testing. But despite this success, screening uptake in recent years has been low.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|